A c c e p t e d M a n u s c r i p t 2 Although major strides have been made in the use of antiretroviral therapy to treat HIV over the past two decades and the rate of new infections has declined, there are still about 2 million new infections globally annually [1] . Recent studies have suggested that the prompt initiation of antiretroviral therapy has dual benefits, both in enhancing the quality and duration of life of those who initiate treatment independent of CD4 count, and in rendering virologically suppressed individuals less infectious to their partners [2] [3] [4] . Some presentations at the recent International AIDS Conference in Durban suggest that wider access to antiretroviral therapy has attenuated the rate of new infections in some settings [5] .
However, the AIDS epidemic is not monolithic, and while epidemic control may be seen in some While the advent of generic antiretrovirals has driven down the cost of treatment in resourceconstrained environments, in developed countries, medication costs are more than $15,000 per year, resulting in an aggregate cost of billions of dollars per year, if all HIV-infected people are to be treated.
Additionally, numerous recent studies have suggested that antiretroviral use as pre-exposure prophylaxis (PrEP) can decrease HIV acquisition by high-risk populations [6] [7] [8] [9] [10] . Thus the question has arisen as to how to best use antiretroviral medications, whether to focus solely on treatment or to include PrEP as part of a global HIV epidemic control strategy.
In the current issue of Clinical Infectious Diseases, Drabo and associates found that for MSM in Los Angeles county that testing every 4 years and immediate initiation of treatment ("test and treat") was the most cost-effective, being less than $20,000 per quality-adjusted life-year (QALY) [11] . Scenarios with HIV testing as frequently as every 6 months followed by immediate treatment were also highly A c c e p t e d M a n u s c r i p t 3 cost-effective. This is not surprising, given that the medication increases individuals' life expectancies and renders them less infectious. What also emerged from their study was that providing PrEP for the highest risk HIV-uninfected MSM in addition to a test and treat strategy would increase the QALY to $27,863 per year in the most cost effective scenario, but that this would lead to further decreases in the number of new HIV infections. Their simulations are helpful in helping policy makers and public health authorities think through optimal strategies for HIV epidemic control, but have to be anchored in the real world of an ongoing domestic and international HIV epidemic.
The rationale for early and prompt treatment is clear cut, but currently, 15% of HIV-infected Americans are unaware of their HIV status [12] , and close to 50,000 new infections occur each year [13] , so any test The reality that virologic suppression of all HIV-infected people is not iminent, provides the rationale for the addition of PrEP. However, with the current cost of PrEP medication and follow-up exceeding $10,000 per year, its use must be judicious and selective. Therefore candidates for PrEP should be among those at highest risk for HIV infection. However, many of these individuals may not be routinely engaged in care because they are otherwise healthy, and may come from socially marginalized poppers) can also help identify a population who would benefit from PrEP [16] .
Another opportunity to enhance the cost effectiveness of PrEP will be to reduce the cost of the medication [17] . The first medications being used for PrEP, tenofovir and emtricitibine in a fixed drug combination, will soon be off patent, which could conceivably reduce their costs [18] . However, other recent drugs that have become generic have not had substantial price reductions. Thus, public health authorities will need to work with the pharmaceutical industry in order to ensure that the transition of the original PrEP regimen to a generic formulation may result in a net cost savings. A challenge for the future is that other medications for PrEP, such as the less nephrotoxic tenofovir alafenamide, are also being developed and might provide favorable, but more expensive, PrEP alternatives [19] . It would be unfortunate to have "antiretroviral apartheid" resulting in some individuals receiving cheaper medications with a higher side effect profile while others with better insurance plans or other means of improved access receiving newer, improved formulations. It is conceivable that the development of long-acting injectable antiretroviral medication may result in PrEP alternatives that may lead to 
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